

TITLE PAGE

Title: Validation and Modification of a Diagnostic Scoring System to Predict Microscopic Colitis.

Short title: Validating and Modifying a Scoring System for Microscopic Colitis.

Authors: John S. Kane^{1,2}, Ruchit Sood^{1,2}, Graham R. Law³, David J Gracie^{1,2}, Natalie To^{1,2}, Matthew J. Gold⁴, Alexander C. Ford^{1, 2}.

¹Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.

²Leeds Institute of Biomedical and Clinical Sciences, University of Leeds, Leeds, UK.

⁴Division of Biostatistics, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, UK.

⁴School of Medicine, University of Leeds, Leeds, UK.

Abbreviations:	CC	collagenous colitis
	CI	confidence interval
	GI	gastrointestinal
	IBS	irritable bowel syndrome
	LC	lymphocytic colitis
	MC	microscopic colitis
	NPV	negative predictive value
	NSAID	non-steroidal anti-inflammatory drug

OR	odds ratio
PPI	proton pump inhibitor
PPV	positive predictive value
ROC	receiver operating characteristics
SD	standard deviation
SSRI	selective serotonin re-uptake inhibitor

Correspondence: Dr. Jack Kane
Leeds Gastroenterology Institute
4th Floor
Bexley Wing
St. James's University Hospital
Beckett Street
Leeds
United Kingdom
LS9 7TF
Email: jackjohnkane@googlemail.com
Telephone: +44113268536
Facsimile: +441132429722

Word count: 3861

ABSTRACT

Objective: Many patients with diarrhoea undergo colonoscopy. If this is macroscopically normal, random biopsies are obtained to rule out microscopic colitis (MC), but most patients have functional disease. Accurate predictors of MC could avoid the need to take biopsies in a substantial proportion of patients, saving money for the health service. We validated a previously described diagnostic scoring system for MC, and incorporated further variables to assess whether this improved performance.

Material and Methods: Consecutive adults with loose stools undergoing colonoscopy in Leeds, UK were included. Demographic and symptom data were collected prospectively. The diagnostic scoring system described previously was applied. In addition, the incorporation of further variables, including drugs associated with MC, number of stools, nocturnal passage of stools, and duration of loose stools, into the scoring system was assessed. Sensitivities, specificities, and positive and negative predictive values were calculated.

Results: Among 242 patients (mean age 51.0 years, 163 (67.4%) female), 26 (10.7%) of whom had MC, a cut off of ≥ 4 on the original scoring system had a sensitivity of 92.3% and specificity of 35.2%. Nocturnal passage of stools and duration of loose stools < 6 months were significant predictors of MC. Incorporating these variables in a new scoring system with a cut off of ≥ 6 identified MC with 95.7% sensitivity and 46.0% specificity.

Conclusions: Incorporating nocturnal passage of stools and duration of loose stools into the scoring system may improve ability to predict MC, and avoid random colonic biopsies in a greater proportion of patients with loose stools.

Keywords: diarrhoea; irritable bowel syndrome; collagenous colitis;
lymphocytic colitis; sensitivity; specificity

INTRODUCTION

Microscopic colitis (MC) is a condition characterised by a clinical history of chronic, watery diarrhoea, normal or near normal macroscopic appearance of the colon during endoscopy, and a distinct histologic pattern (1). Two main histologic subtypes have been described, with collagenous colitis (CC) associated with a characteristic thick band of collagen beneath the surface epithelium, and lymphocytic colitis (LC) with a diffuse proliferation of intra-epithelial lymphocytes. A recent meta-analysis reported a pooled incidence rate of CC of 4.14 per 100,000 person-years, and of LC of 4.85 per 100,000 person-years (2), suggesting that both conditions are relatively common.

Chronic diarrhoea is a common complaint in the general population in community-based surveys (3, 4). More than one-in-four individuals with chronic diarrhoea will consult a physician (5), and a proportion of these individuals will be referred on for further investigation. In the context of a macroscopically normal or near normal colonoscopy in a patient with chronic diarrhoea, most endoscopists would obtain random colonic biopsies to look for MC, but the yield of this approach is low (6). This is because many individuals undergoing colonoscopy with diarrhoea as an indication will meet diagnostic criteria for irritable bowel syndrome (IBS) (7), the symptoms of which may overlap with those of MC (8), and others will have no organic explanation for their symptoms, and will be labelled as suffering from functional diarrhoea. Given the relatively low prevalence of MC in patients with chronic diarrhoea, there is therefore likely to be a high cost for obtaining and analysing these biopsy specimens.

In a previous retrospective study we demonstrated that applying a diagnostic scoring system combining known risk factors for, and presenting features of, MC

predicted patients with the disorder after interpretation of random colonic biopsy specimens (9). In this study variables significantly associated with presence of MC in a derivation cohort included age ≥ 50 years, female gender, use of proton pump inhibitors (PPIs) or non-steroidal anti-inflammatory drugs (NSAIDs), the presence of weight loss, and the absence of abdominal pain. When applied in a validation cohort the scoring system had high sensitivity in identifying patients with MC, but avoided the need for random colonic biopsies in a substantial proportion of patients with chronic diarrhoea. This scoring system has since been validated independently in two other cohorts (10, 11), and performed similarly.

Using a retrospective cohort had certain limitations. In particular, there was reliance on documentation by the consulting physician of both clinical symptoms and medication use. As a result, data on the use of medications such as selective serotonin re-uptake inhibitors (SSRIs) and statins, and symptoms such as duration of diarrhoea, nocturnal passage of stools, or number of stools passed, which have all been shown previously to be associated with MC (12, 13), were either not available, or may have been compromised by the retrospective nature of the study. We therefore aimed to validate the use of this diagnostic scoring system in a prospective cohort of patients presenting with chronic diarrhoea, as well as to assess whether the inclusion of the aforementioned variables improved its performance.

METHODS

Participants and Setting

All individuals newly referred from primary care to secondary care for consideration of investigation of gastrointestinal (GI) symptoms were potentially eligible for this study. Unselected consecutive new patients aged ≥ 18 years were approached in the GI outpatient clinics of Leeds Teaching Hospitals Trust, West Yorkshire. The hospitals provide secondary care services to a local population of almost 800,000 people in the North of England. There were no exclusion criteria, other than an inability to understand written English, as the questionnaires we used were self-administered. Potentially eligible subjects were provided with a study information sheet at their initial clinic visit, prior to consultation with a Gastroenterologist. Those who agreed to participate were asked to provide written informed consent at that visit. The local research ethics committee approved the study, with recruitment commencing in January 2014, and continuing until December 2015.

Data Collection and Synthesis

Demographic and Symptom Data

All demographic and symptom data were collected prospectively at the initial clinic visit, and hence prior to referral for colonoscopy. Demographic data of interest included the age of the patient at the time of recruitment, gender, and the current use of any medications that could be of potential relevance in the aetiology of MC (NSAIDs, PPIs, statins, or SSRIs) (12). Symptom data were captured using the Rome III

diagnostic questionnaire for the adult functional GI disorders (14). All questionnaire data were entered into a database by trained researchers who were not involved in the clinical care of the patient, thus ensuring assessors were blinded to symptom status.

Definition of the Symptoms of Interest

Only individuals with loose, mushy, or watery stools according to the Rome III diagnostic questionnaire were included in this study. Duration of loose, mushy, or watery stools was recorded as ≥ 6 months, or < 6 months, again according to this questionnaire. The presence of abdominal pain or discomfort was recorded, using the Rome III questionnaire, with a symptom frequency of abdominal pain or discomfort occurring once a week or more used to define its presence. Four or more stools per day, and nocturnal passage of stool, were recorded as occurring never or rarely, sometimes, often, most of the time, or always, with a symptom frequency of sometimes or greater used to define their presence. Finally, all patients were asked to report whether or not they had lost weight, as a dichotomous yes/no response.

Colonoscopic and Histopathological Data

All included patients underwent complete colonoscopy to the caecum or terminal ileum. The endoscopy units in Leeds Teaching Hospitals Trust employ colonoscopes from both Olympus and Fujinon. Bowel preparation was either a combination of polyethylene glycol and sodium picosulfate, or polyethylene glycol alone, depending on renal function. The responsible physician performing colonoscopic examinations remained blinded to the questionnaire data of the patient. Only patients with a macroscopically normal colonic mucosa at colonoscopy were included in this

study. Random colonic biopsies were taken in all patients, the number of which was at the discretion of the individual endoscopist, although standard departmental policy is to take two from the right colon, two from the left colon, and two from the rectum. These specimens were interpreted by experienced GI histopathologists, who remained blinded to the questionnaire data of the patient.

Reference Standard

The diagnosis of MC was according to the following criteria: CC was defined as the presence of a subepithelial collagen band of $\geq 10\mu\text{m}$ in thickness, in association with diffuse chronic inflammation; LC was defined using a threshold of >20 intra-epithelial lymphocytes per 100 epithelial cells, with associated diffuse chronic inflammation, but no thickening of the subepithelial collagen band. Other investigators have demonstrated that there is little inter-observer variability in the diagnosis of MC (15).

Statistical Analysis

The associations between the demographic and symptom data described above and the presence of MC were explored using univariate analysis in our previous study (9), and expressed as odds ratios (OR) with a 95% confidence interval (CI). Those variables that demonstrated statistically significant univariate ORs were included in a diagnostic scoring system to predict the presence of MC. The methodology used has been reported elsewhere (9). Briefly, the regression coefficients of any statistically significant predictors on univariate analysis were changed into item assigned scores by dividing with the smallest coefficient (0.155), and rounding up to the nearest integer. These individual item scores were then summed to create a total score, which varied

from a possible total of -8 to +38, and signified the summary measure of risk for MC. This methodology is similar to that used to create other predictive scores in gastroenterology, including scores to predict peptic ulcer perforation, mortality after GI haemorrhage, and need for endoscopic intervention in patients with GI haemorrhage (16-18).

The optimal cut off using this scoring system was $\geq+8$, which demonstrated a sensitivity and specificity of 94.1% and 48.6%, respectively, in the derivation cohort of the original study, and 90.5% and 45.3% in the validation cohort (9). However, given that a missed diagnosis of MC may be problematic for patients, we also assessed the performance of a lower threshold of $\geq+4$ to predict MC, in order to increase sensitivity. At this cut-off the diagnostic scoring system performed with a sensitivity of 98.8% and specificity of 37.1% in the derivation cohort, and 94.6% and 32.6% in the validation cohort (9).

The primary aims of the present study were two-fold. Firstly, to validate the diagnostic system using a cut off of either $\geq+8$ or $\geq+4$, but this time in a cohort of patients with prospective, rather than retrospective, data collection. Secondly, to assess the effect of the incorporation of other variables, including use of statins or SSRIs, and symptom data such as duration of loose, mushy, or watery stools, passage of four or more stools per day, and nocturnal passage of stool on the performance of the score, as these data were either unavailable in the previous study, or their accuracy and completeness may have been hampered by the retrospective nature of the data collection.

We therefore performed new univariate analyses for statin use, SSRI use, passage of four or more stools per day, nocturnal passage of stools, and duration of

loose, mushy, or watery stools in this prospective cohort of patients. Again, the regression coefficients of any statistically significant predictors among these five variables after univariate analysis were changed into item assigned scores by dividing with the smallest coefficient from the derivation study (0.155), and rounded up to the nearest integer (9). These individual item scores were then summed to create a total score, which varied from a possible total of -14 to +42.

We assessed the performance of the original and the modified diagnostic scoring systems in predicting the presence of MC, using a receiver operating characteristics (ROC) curve, and the total area under the curve was calculated. We calculated sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), and their 95% CIs. All analyses were performed using StatsDirect version 2.7.2 (StatsDirect Ltd, Sale, Cheshire, England), and a Microsoft Excel spreadsheet (XP professional edition; Microsoft Corp, Redmond, WA, USA). These calculations were checked using Meta-DiSc® version 1.4 (Universidad Complutense, Madrid, Spain).

RESULTS

In total, 242 patients with loose, mushy, or watery stools undergoing complete colonoscopy with macroscopically normal colonic mucosa and random colonic biopsies obtained were included. The mean age of these individuals was 50.5 years (range 18 to 81 years) and 163 (67.4%) were female. Of the included subjects, 26 (10.7%) patients were diagnosed with MC on histological grounds: 14 with CC, and 12 with LC. The remaining 216 patients had a macroscopically normal colonoscopy and normal random colonic biopsies. None of the 242 included patients had coeliac disease. Demographic and symptom data for the 242 patients are provided in Table 1.

Performance of the Original Scoring System

The ROC curve for the original diagnostic scoring system in predicting the presence of MC demonstrated an area under the curve of 0.81 (Figure 1). Using a cut off $\geq +8$, the scoring system correctly identified 23 (88.5%) of 26 MC patients, and would have avoided unnecessary random colonic biopsies in 99 (45.8%) of 216 patients without MC. Sensitivity, specificity, PPV, and NPV, along with 95% CIs, at this threshold are provided in Table 2. Of the three patients with MC the score failed to identify, two were female (mean age 46.7 years, range 44 to 49 years), all had LC, and one met the Rome III criteria for IBS with diarrhoea.

When we assessed the performance of the lower threshold of $\geq +4$ to predict MC, the diagnostic scoring system correctly identified 24 (92.3%) of 26 patients with MC, and would have avoided unnecessary biopsies in 76 (35.2%) of 216 patients without MC. The sensitivity, specificity, PPV, and NPV and their 95% CIs at this threshold are also provided in Table 2.

Performance of the Modified Scoring System

Odds ratios for the association of each of the four additional items assessed for the modified diagnostic scoring system with the presence of MC, along with 95% CIs, are presented in Table 3. There was no significant association between use of statins or SSRIs, or the passage of four or more stools per day, and MC, and these items therefore did not contribute to the total score. Each of the remaining item scores ranged from -6 to +10. These were summed to obtain the total score for each patient, which ranged from -14 to +42. The ROC curve for this diagnostic scoring system in predicting the presence of MC is shown in Figure 2, with an area under the curve of 0.82.

Using a cut off of ≥ 8 to predict the presence of MC correctly identified 21 (91.3%) of 23 MC patients, and would have avoided unnecessary random colonic biopsies in 102 (50.5%) of 202 patients without MC. Sensitivity, specificity, PPV, and NPV, along with 95% CIs, at this threshold are provided in Table 2. Using a cut off of ≥ 6 to predict the presence of MC, in order to maximise sensitivity, meant that 22 (95.7%) of 23 patients with MC would have been correctly identified, while random colonic biopsies would still have been avoided in 93 (46.0%) of 202 patients without MC.

DISCUSSION

This study was designed to validate a diagnostic scoring system based on clinical data alone (9), which could distinguish between patients with MC and those with likely functional bowel disease, in a prospective cohort, as well as to incorporate other potentially key variables to assess whether this improved its performance. Using a cut off of $\geq+8$, the scoring system described previously had a sensitivity of 88.5% and would have avoided random colonic biopsies in almost 46% of patients. Using a cut off of $\geq+4$, sensitivity was 92.3%, and biopsies would have been avoided in >35%.

Incorporating the additional clinical features such as nocturnal passage of stool, and the duration of loose, mushy or watery stools of <6 months into a modified scoring system, and using a cut off of $\geq+6$ improved sensitivity to almost 96%, and would have avoided biopsies in 46% of patients, which is a similar performance to the original scoring system in the derivation cohort. Given that the costs of analysis of colonic biopsy specimens were £80 per case in the UK in 2014-2015 (19), applying the modified scoring system using this cut off in this cohort would have saved >£5500, or >£450 per case of MC diagnosed. These savings do not take into account the reduction in procedure time by negating the need for colonic biopsies.

Strengths of this study include the validation of the scoring system in a prospective cohort, the use of a validated questionnaire to capture symptom data, and the rigorous data collection for medication use. These features of the study design are an improvement over our previous study (9), with methodology similar to that of the validation cohort reported by Cotter *et al.*, in which the authors were able to incorporate information available from a standardised form completed by the patient at the time of their clinical encounter (10). In addition, the study was designed to adhere closely to the

STARD guidelines for the reporting of studies of diagnostic accuracy, with consecutive patients recruited, assessors blinded to questionnaire data, a standardised departmental policy for obtaining random colonic biopsies, and an accepted reference standard used. Finally, the fact that the majority of patients recruited were unselected referrals to secondary care means that the results are likely to be generalisable to Gastroenterologists consulting with individuals with suspected MC in usual clinical practice.

In terms of limitations, our study population included a relatively small number of cases of MC compared with the previous derivation and validation cohorts (9). However, in our previous study we included all cases of MC diagnosed within a 1-year period, but only a random selection of patients with chronic diarrhoea without MC, colonoscoped during the same time period, as controls. This may have led to an overestimation of the performance of the scoring system in the previous study, because the arbitrary size of the control group could theoretically result in an artificially lower false positive rate, leading to a higher specificity and positive predictive value. In addition, despite the smaller number of cases in the current study the characteristics of patients with MC, including mean age, gender, and PPI and NSAID use were remarkably similar to those in the previous study. Other weaknesses include the fact that we could not include other features from the clinical history, such as whether a particular drug had been introduced recently, any history of autoimmune disease, or abnormal blood results, which may be associated with a diagnosis of MC, as the questionnaire we used did not capture these data. In a study by Macaigne *et al.* recently introduced drugs were strongly associated with an increased risk of MC (13), although this was not seen in another case-control study (20). Finally, we did not study whether

the degree of weight loss reported by the patient could improve the performance of the score, which may have been a more objective approach than the dichotomous variable we used.

As in the previously reported derivation and validation cohorts (9), patients with MC were older, predominantly female, had increased PPI and NSAID usage, were more likely to have experienced weight loss, and also less likely to report abdominal pain. Some of these associations have been noted in other prospective and retrospective cohorts (13, 21, 22), and in a recent meta-analysis (2), although these findings are not consistent across all studies. Both Cotter *et al.* and Macaigne *et al.* reported that female gender was not an independent predictor for MC (10, 13). However, in the larger of these studies 70% of the control group met diagnostic criteria IBS, which is commoner in women (23).

In the modified scoring system, our prospective study design also allowed us to record more comprehensive information on medication use. Statins and SSRIs have both been implicated in the development of MC (12), but neither were shown to be significantly associated with MC in our analysis. There was a trend towards SSRI use being more likely in those with MC, so it may be that our study was not adequately powered to examine this, although the lack of an association with either of these drugs is in line with a previous meta-analysis (2). We were also able to include nocturnal diarrhoea, number of stools, and duration of symptoms, with more complete data collection for the former variable in the current study. The presence of nocturnal passage of stools and a duration of diarrhoea <6 months were both associated with MC. The latter is in keeping with the findings of Macaigne *et al.*, who demonstrated that diarrhoea for <12 months was an independent predictor of MC (13).

Although the cut offs we used on the original and modified scoring systems were chosen to maximise sensitivity, as a missed diagnosis of MC may be unacceptable to both patients and physicians, a score of ≥ 6 on the modified scoring system appeared to perform better than a score of ≥ 4 on the original scoring system in the previous validation cohort (9), with slightly higher sensitivity and much higher specificity. This was despite the fact that the prevalence of MC was lower in the present study (10.7% versus $>16\%$ in the derivation and validation cohorts in the original study). Other investigators have demonstrated a similar sensitivity of the original scoring system. Cotter *et al.* reported a sensitivity of 95%, but a specificity of 25% using a cut off of ≥ 4 in 617 patients (10), while Regner and Gerich reported that sensitivity was 89% and specificity was 40% in 119 patients, although it should be noted that 30.3% of patients had MC in the latter study (11).

The modified scoring system therefore appears to have the potential to avoid a greater number of random colonic biopsies, without an increased miss rate for MC, in patients with chronic diarrhoea. Its performance needs to be assessed in other centres, also using a prospective study design, and with patients recruited as part of routine clinical practice. In the interim, however, these data suggest that nocturnal passage of stools and a duration of diarrhoea <6 months are also associated with a diagnosis of MC, as well as providing further confirmation of previously reported associations between increasing age, female gender, PPI or NSAID use, presence of weight loss, and absence of abdominal pain and MC.

In summary, the original scoring system performed with a high sensitivity of 92.3%, but a low specificity of 35.2% and a low positive predictive value of 14.6%, using a cut off of ≥ 4 . Incorporating the additional clinical features such as nocturnal

passage of stool, and the duration of loose, mushy or watery stools of <6 months into a modified scoring system, and using a cut off of $\geq +6$ improved sensitivity to 95.7%, and specificity to 46.0%, although positive predictive value remained low at 16.8%. Both the original and the modified diagnostic scoring system have potential clinical utility, as they are based only on features that are obtained through a verbal conversation with patients, without the need for laboratory investigations, the results of which may not be available immediately. They could be applied either in the clinic setting or immediately prior to colonoscopy, allowing real-time use. While the study was not designed to evaluate the economic implications of these scoring systems, we suggest that they have the potential to reduce both endoscopic time and overall costs associated with diagnosing MC. However it remains unclear whether a negative score should be used to avoid taking random colonic biopsies from patients with chronic diarrhoea with a macroscopically normal colonoscopy, or to avoid colonoscopy altogether in younger patients without clear risk factors for MC or other organic pathology. Further research is therefore required to determine the optimal role of the scoring systems within overall management pathways for chronic diarrhoea, especially as part of systems to deliver high quality healthcare at reduced costs.

ACKNOWLEDGEMENTS

We are grateful to Dr. Olorunda Rotimi and Dr. Simon M. Everett for their assistance with the original derivation and validation of this diagnostic scoring system.

FUNDING

None.

DISCLOSURES

JSK: none. RS: none. GRL: none. DJG: none. NT: none. MJG: none. ACF: none.

STATEMENTS OF INTEREST

Guarantor of the article: JSK is guarantor.

Specific author contributions: JSK, RS, GRL, DJG, NT, MJG, and ACF conceived and drafted the study. NT, MJG, DJG, and RS collected all data. ACF, RS, DJG, MJG, GRL, NT, and JSK analysed and interpreted the data. JSK and ACF drafted the manuscript. All authors contributed to and approved the final draft of the manuscript.

REFERENCES

- 1 Magro F, Langner C, Driessen A, Ensari A, Geboes K, Mantzaris GJ et al. European consensus on the histopathology of inflammatory bowel disease. *J Crohns Colitis*. 2013; 7: 827-51.
- 2 Tong J, Zheng Q, Zhang C, Lo R, Shen J, Ran Z. Incidence, prevalence, and temporal trends of microscopic colitis: A systematic review and meta-analysis. *Am J Gastroenterol*. 2015; 110: 265-76.
- 3 Chen LY, Ho KY, Phua KH. Normal bowel habits and prevalence of functional bowel disorders in Singaporean adults - findings from a community based study in Bishan. *Singapore Med J*. 2000; 41: 255-8.
- 4 Basaranoglu M, Celebi S, Ataseven H, Rahman S, Deveci SE, Acik Y. Prevalence and consultation behavior of self-reported rectal bleeding by face-to-face interview in an Asian community. *Digestion*. 2008; 77: 10-5.
- 5 Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG et al. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci*. 1993; 38: 1569-80.
- 6 Genta RM, Sonnenberg A. The yield of colonic biopsy in the evaluation of chronic unexplained diarrhea. *Eur J Gastroenterol Hepatol*. 2015; 27: 963-7.

- 7 Patel P, Bercik P, Morgan DG, Bolino C, Pintos-Sanchez MI, Moayyedi P *et al.* Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey. *Scand J Gastroenterol.* 2015; 50: 816-23.
- 8 Kamp EJ, Kane JS, Ford AC. Irritable bowel syndrome and microscopic colitis: A systematic review and meta-analysis. *Clin Gastroenterol Hepatol.* 2016; 14: 659-68.
- 9 Kane JS, Rotimi O, Everett SM, Samji S, Michelotti F, Ford AC. Development and validation of a scoring system to identify patients with microscopic colitis. *Clin Gastroenterol Hepatol.* 2015; 13: 1125-31.
- 10 Cotter TG, Binder M, Pardi DS. Validation of a scoring system to predict microscopic colitis in a cohort of patients with chronic diarrhea. *Clin Gastroenterol Hepatol.* 2016; 14: 777-8.
- 11 Regner EH, Gerich ME. Validation of a proposed scoring system to identify patients with microscopic colitis prior to colonoscopy. *Am J Gastroenterol.* 2015; 110 (Supplement 1s): S573.
- 12 Beaugerie L, Pardi DS. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. *Aliment Pharmacol Ther.* 2005; 22: 277-84.

13 Macaigne G, Lahmek P, Locher C, Lesgourgues B, Costes L, Nicolas MP et al. Microscopic colitis or functional bowel disease with diarrhea: a French prospective multicenter study. *Am J Gastroenterol*. 2014; 109: 1461-70.

14 Whitehead WE, and the Validation Working Team Committee in association with the Rome Questionnaire C. Development and validation of the Rome III diagnostic questionnaire. In: *Drossman DA, editor Rome III: The functional gastrointestinal disorders, 3rd edition Virginia: Degnon Associates Inc.* 2006: 835-53.

15 Limsui D, Pardi DS, Smyrk TC, Abraham SC, Lewis JT, Sanderson SO et al. Observer variability in the histologic diagnosis of microscopic colitis. *Inflamm Bowel Dis*. 2009; 15: 35-8.

16 Suriya C, Kasatpibal N, Kunaviktikul W, Kayee T. Development of a simplified diagnostic indicators scoring system and validation for peptic ulcer perforation in a developing country. *Clin Exp Gastroenterol*. 2012; 5: 187-94.

17 Rockall TA, Logan RF, Devlin HB, Northfield TC. Risk assessment after acute upper gastrointestinal haemorrhage. *Gut*. 1996; 38: 316-21.

18 Blatchford O, Murray WR, Blatchford M. A risk score to predict need for treatment for upper-gastrointestinal haemorrhage. *Lancet*. 2000; 356: 1318-21.

19 National schedule of reference costs: spell costs.

<https://www.gov.uk/government/publications/nhs-reference-costs-2014-to-2015>.

- 20 Fernandez-Banares F, de Sousa MR, Salas A, Beltran B, Piqueras M, Iglesias E et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. *Inflamm Bowel Dis.* 2013; 19: 411-7.
- 21 Larsson JK, Sjoberg K, Vigren L, Benoni C, Toth E, Olesen M. Chronic non-bloody diarrhoea: a prospective study in Malmo, Sweden, with focus on microscopic colitis. *BMC Res Notes.* 2014; 7: 236.
- 22 O'Toole A, Coss A, Holleran G, Keegan D, Doherty G, Sheahan K et al. Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population. *Int J Colorectal Dis.* 2014; 29: 799-803.
- 23 Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: Systematic review and meta-analysis. *Am J Gastroenterol.* 2012; 107: 991-1000.

Table 1: Demographic Characteristics and Symptom Data of Patients with Diarrhoea with MC, and Patients with Diarrhoea without MC.

	Patients with diarrhoea with MC (n = 26)	Patients with diarrhoea without MC (n = 216)
Mean age (SD)	62.5 (10.2)	49.1 (15.9)
Age \geq50 years (%)	22 (84.6)	115 (53.2)
Female gender (%)	23 (88.5)	140 (64.8)
Current PPI use (%)	11 (42.3)	43 (19.9)
Current NSAID use (%)	4 (15.4)	8 (3.7)
Current statin use (%)	4 (15.4)	19 (8.8)
Current SSRI use (%)	4 (15.4)	11 (5.1)
Abdominal pain or discomfort (%)	14 (53.8)	132 (61.1)
Weight loss (%)	14 (53.8)	60 (27.8)
Nocturnal passage of stool (%)	20 (76.9)	95 (44.0)
Duration of loose, mushy, or watery stools of \geq6 months (%)	9 (39.1)	138 (68.3)

Table 2: Sensitivity, Specificity, Positive, and Negative Predictive Values of the Original and Modified Diagnostic Scoring Systems in Patients with Diarrhoea.

		No. with MC with a score above the cut-off	No. without MC with a score above the cut-off	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	Negative predictive value (95% CI)
Original scoring system	Score of ≥ 8	23 / 26	117 / 216	88.5% (71.0% - 96.0%)	45.8% (39.3% - 52.5%)	16.4% (11.2% - 23.5%)	97.1% (91.7% - 99.0%)
	Score of ≥ 4	24 / 26	140 / 216	92.3% (75.9% - 97.9%)	35.2% (29.1% - 41.8%)	14.6% (10.0% - 20.9%)	97.4% (91.1% - 99.3%)
Modified scoring system	Score of ≥ 8	21 / 23	100 / 202	91.3% (73.2% - 97.6%)	50.5% (43.7% - 57.3%)	17.4% (11.6% - 25.1%)	98.1% (93.3% - 99.5%)
	Score of ≥ 6	22 / 23	109 / 202	95.7% (79.0% - 99.2%)	46.0% (39.3% - 52.9%)	16.8% (11.4% - 24.1%)	98.9% (94.2% - 99.8%)

Table 3: Item Scores within the Modified Diagnostic Scoring System.

Item	Odds ratio	95% CI	Regression coefficient	Used within the Scoring System	Item score*
Nocturnal passage of stool present	4.47	1.74 – 11.4	1.496	Yes	+10
≥4 stools per day	1.38	0.63 – 3.03	0.322	No	N/A†
Duration of loose, mushy, or watery stools ≥6 months present	0.38	0.17 – 0.89	-0.956	Yes	-6
Statin use	1.62	0.51 – 5.11	0.482	No	N/A†
SSRI use	3.24	0.96 – 11.0	1.176	No	N/A†

*Derived by dividing the regression coefficient for each item by the regression coefficient for the item from the derivation study with the lowest value (0.155)

†N/A; not applicable, not used in the scoring system

FIGURE LEGENDS

Figure 1. ROC curve for the Original Diagnostic Scoring System in Predicting MC.

Figure 2. ROC curve for the Modified Diagnostic Scoring System in Predicting MC.